Firefly Neuroscience Q3 cash $1.2M; partners with Bright Minds, Novartis, Takeda

FIREFLY NEUROSCIENCE, INC.

2025-Q3 EPS reported -$1.15 revenue$55,000

Cash $1.2M as of Sept 30, 2024; shares outstanding 8,503,365 as of Nov 12.
Partnered with Bright Minds, Novartis, Takeda for BNA platform in drug development.
Integrated BNA technology at Neurology Consultants of Dallas; partnered with Zeto for EEG devices.
Appointed Dr. Stella Vnook to Board of Directors.
Completed merger with WaveDancer; listed on Nasdaq under ticker AIFF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.